Resultados de la búsqueda 21-30 of 14641 for breast cancer
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to find ...
Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy. Rochester, Minn. The goal of this clinical research study is to ...
... Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are ...
Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...
The goal of this research is to identify risk profiles of women (with particular emphasis on Hispanic women) for breast cancer based on family history, ...
The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...
Study of Breast Cancer Risk Assessment in Female Patients with Benign Breast Disease. Rochester, Minn., Jacksonville, Fla. The purpose of this study is to to ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?